Nivolumab Plus Chemoradiation Safe For Advanced Head, Neck Cancer


Nivolumab immunotherapy appeared safe and feasible to administer in conjunction with radiation and chemotherapy for patients with newly diagnosed local-regionally advanced squamous cell carcinoma of the head and neck, according to results from the RTOG Foundation 3504 trial scheduled for presentation at the Multidisciplinary Head and Neck Cancers Symposium.